LGND

Business Context and Reporting Period

Ligand Pharmaceuticals Inc. (Ligand) is a biotechnology company focused on discovering and developing drugs for thrombocytopenia, anemia, cancer, and hormonal disorders. This Form 10-Q covers the quarterly period ended September 30, 2008. The company operates primarily as a royalty-driven entity following the sale of its commercial product lines (AVINZA and Oncology products) in 2006 and 2007, which are now reported as discontinued operations. Ligand relies heavily on royalties from AVINZA sales and milestone payments from collaborations with partners such as GlaxoSmithKline, Wyeth, and Pfizer.

Key Financial Metrics

Debt and Liquidity: Total liabilities were $132.9 million. Current liabilities included $29.2 million in accrued liabilities and $10.8 million in the current portion of co-promote termination liability. Equipment financing obligations totaled $0.9 million outstanding. Management believes current cash, investments, and royalty revenues are sufficient to fund operations for at least the next twelve months.

Material Changes vs. Prior Period

• Revenue Growth: Royalty revenue increased significantly to $14.9 million for the nine months ended September 30, 2008, compared to $6.6 million in the prior year period, driven by AVINZA sales.
• Net Loss vs. Net Income: The company reported a net loss of $28.5 million for the nine months ended September 30, 2008, a stark contrast to the $275.8 million net income in the same 2007 period. The 2007 income was heavily influenced by a $317.3 million gain on the sale of the AVINZA product line (discontinued operations).
• Discontinued Operations Loss: Discontinued operations resulted in a net loss of $4.8 million for the nine months ended September 30, 2008, primarily due to a $13.0 million litigation settlement with the Salk Institute and changes in estimates related to the Oncology product line sale.
• Cash Position: Cash and cash equivalents decreased from $76.8 million at December 31, 2007, to $11.8 million at September 30, 2008. This reduction was driven by operating cash outflows of $26.8 million and investing outflows of $35.4 million (primarily net purchases of short-term investments).
• Operating Expenses: Research and development expenses decreased to $19.7 million (nine months 2008) from $34.2 million (nine months 2007), largely due to workforce reductions and lower research costs. General and administrative expenses also decreased to $20.6 million from $26.5 million, despite increased legal fees related to litigation settlements.

Guidance, Outlook, Risks, and Unusual Items

• Merger with Pharmacopeia: On September 24, 2008, Ligand entered into a definitive agreement to acquire Pharmacopeia, Inc. in a primarily stock-for-stock transaction. The exchange ratio is variable based on Ligand's stock price, with Pharmacopeia shareholders receiving approximately 16% of the combined company. The merger is subject to shareholder approval and regulatory conditions.
• Litigation Risks:
  • Salk Institute: Settled for $13.0 million ($9.5 million immediate, $3.5 million deferred), recorded as a loss in discontinued operations.
  • Rockefeller University: Ongoing lawsuit alleging breach of a 1992 license agreement. Rockefeller seeks $1.9 million plus 25% of future payments related to Promacta (eltrombopag) and other products. Ligand has filed counterclaims.
  • SEC Investigation: An ongoing investigation into the restatement of financial statements for 2002-2004 continues. Management cannot assess the duration or cost.
  • Pharmacopeia Merger Litigation: A putative class action was filed challenging the merger terms, seeking to enjoin the transaction.
• Investment Impairment: Ligand holds a defaulted commercial paper investment from Golden Key Ltd. ($5.0 million cost). Management estimates a recovery of $2.3 million and recorded a $1.4 million impairment loss for the nine months ended September 30, 2008.
• Product Pipeline:
  • Eltrombopag (Promacta): Collaboration with GlaxoSmithKline. FDA action pending for chronic ITP treatment. Royalties are contingent on sales and the outcome of the Rockefeller litigation.
  • Lasofoxifene: Collaboration with Pfizer. FDA Advisory Committee voted favorably in September 2008; final decision pending.
  • Bazedoxifene: Collaboration with Wyeth. FDA has issued approvable letters but requested additional data on stroke and venous thrombotic events.
• AVINZA Royalties: Beginning October 2008, royalty payments from King Pharmaceuticals will shift from quarterly to an annual calendar year basis, which may impact cash flow timing.

Investor Verification Checklist

• Merger Completion: Verify the status of the Pharmacopeia merger, including shareholder approval and the resolution of the class action lawsuit filed to enjoin the transaction.
• Rockefeller Litigation Outcome: Monitor the progress of the lawsuit with Rockefeller University, as a loss could require Ligand to pay 25% of future Promacta royalties, significantly impacting future revenue.
• AVINZA Royalty Timing: Confirm the impact of the shift to annual royalty payments from King Pharmaceuticals on quarterly cash flow projections.
• Regulatory Approvals: Track FDA decisions on Promacta (eltrombopag) and Lasofoxifene, as these are critical for future royalty revenue streams.
• SEC Investigation: Monitor for any updates regarding the SEC investigation into historical financial restatements, which could result in fines or further legal costs.
• Investment Recovery: Assess the final recovery amount on the defaulted Golden Key Ltd. commercial paper investment.